Compare BIPC & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIPC | IRTC |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 4.8B |
| IPO Year | 2019 | 2016 |
| Metric | BIPC | IRTC |
|---|---|---|
| Price | $48.87 | $126.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $53.00 | ★ $209.69 |
| AVG Volume (30 Days) | 596.4K | ★ 631.6K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 3.66% | N/A |
| EPS Growth | N/A | ★ 61.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $747,138,000.00 |
| Revenue This Year | $7.93 | $18.26 |
| Revenue Next Year | $5.51 | $15.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 26.24 |
| 52 Week Low | $32.08 | $92.52 |
| 52 Week High | $51.72 | $210.01 |
| Indicator | BIPC | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 53.28 | 31.27 |
| Support Level | $43.48 | N/A |
| Resistance Level | $51.72 | $167.19 |
| Average True Range (ATR) | 1.23 | 8.25 |
| MACD | -0.10 | -1.60 |
| Stochastic Oscillator | 43.56 | 14.24 |
Brookfield Infrastructure Corp is an indirect subsidiary of the partnership of the diversified infrastructure owner and operators. Its business is comprised of a U.K. regulated distribution operation, a Brazilian regulated natural gas transmission operation and an international intermodal logistics operation. Geographically, the company generates a majority of its revenue from Brazil and rest from United Kingdom and the United States.
iRhythm Holdings Inc formerly, iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.